Pharmaceuticals Biotechnology and Life Sciences
featured
During a conference call on drugmaker Merck& Co.' s fourth-quarter results, executives discussed some of their experimental drugs in development, including suvorexant, a new type of insomnia medicine designed to limit the morning grogginess common with sleep aids. QUESTION: What prospects do you see for suvorexant if it's approved?
» Read More
More
-
Take a company that’s being managed into the ground, add an activist investor to stir things up, and you’ve got a stock that should go higher. Tonight, Cramer’s got a play that fits the model.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
This past weekend BSTE got a takeover bid at a 53% premium to the price Cramer recommended the stock at four weeks ago. If you missed out on that play, he might have found another company in the sector that could do just as well.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Right now, the hottest part of the market is non-pharma health care because it is immunized from the subprime lending troubles. So each night this week Cramer will highlight one stock from the sector in hopes of finding you the next big thing.
-
The fact that Cramer wants you in this sector may confuse you. Yes, we know, this group is responsible for the subprime-lending problem we’re seeing today, but this could end up helping investors.
-
After the trauma of a 416-point drop in the market, Cramer likes to go fishing – bottom fishing, actually. He has 25 years of experience angling through the wrecks of portfolios that belonged to less experienced fisherman and women, and today he’s going to share his secrets with you.
-
If the Dems take over the White House in 2008, the diagnostics services sector is where you’ll want to be. That’s because a Democrat in the White House will mean no more buddy-buddy relationship between the government and pharmaceutical companies.
-
Genentech shares traded lower after data from a clinical trial indicated that a lower dosage of the blockbuster cancer drug Avastin was as effective as the standard dose for lung cancer patients.
-
As far as Cramer is concerned, the Sirius-XM Satellite Radio proposed deal is just the first of many coming over the next two years as corporations race to beat a potential Democratic White House in 2008. But which companies are in the best poised to profit?
-
Warren Buffett made a fortune investing in boring stocks, and he often advised would-be billionaires to do the same. In fact, finding below-the-radar value plays has been a key strategy on Wall Street since the 1949 tome, The Intelligent Investor, written by Buffett mentor Benjamin Graham. Today on “Street Signs,” Erin Burnett cajoled a few stock picks out of another soft-spoken Midwestern investor, and true to form, they’re companies you’ve probably never heard of.
-
Genentech has sent a letter alerting eye doctors to the risk of stroke from Lucentis, its drug for treating age-related macular degeneration, a spokeswoman said.
-
The findings on Aranesp and colon cancer treatment Vectibix were released late on Thursday, as the world's largest biotechnology company reported a marginal increase in fourth-quarter profit.
-
Genentech, a maker of medical biotechnology products, reported earnings of 61 cents a share for the fourth quarter, better than analysts estimates of 56 cents.
-
Amylin Pharmaceuticals has felt the pressure of late since Merck released a diabetes drug to rival its own Byetta. And there’s no relief in sight with Novartis not far behind in getting approval for its Galvus treatment. CNBC’s Mike Huckman spoke with Amylin CEO Ginger Graham about how the competition is affecting the company.
-
The U.S. Supreme Court sided with MedImmune and reinstated the company's lawsuit challenging the validity of a key Genentech patent.
-
As we've said--CNBC pharmaceuticals reporter Mike Huckman is at the 25th Annual JPMorgan Healthcare Conference in San Francisco this week. This morning on “Squawk on the Street” he got a chance to talk to Celgene Chairman and CEO Sol Barer. Barer’s company is up 365% over the past three years and has a cancer-fighting drug he says has “multibillion-dollar potential.”
-
Google, which seems to surpass the competition in any market it enters, is now leading yet another category – Fortune‘s “100 Best Companies To Work For.” Andrew Serwer, editor at large for the magazine, spoke to Joe Kernen on “Squawk Box” this morning about why the internet bellwether’s employees are so happy.
-
BioCryst Pharmaceuticals has won a $102.6 million government contract for advanced development of its influenza antiviral drug, peramivir.
-
CNBC’s Bob O’Brien talked with Michelle Caruso-Cabrera about his stock winners and losers for the day so far. Some poor December retail sales numbers and less-than-stellar economic data caused sharp losses in the Dow, but a semiconductor rally is sparking a comeback. O’Brien says Intel is leading the pack.
-
As we've been writing--CNBC pharmaceuticals reporter Mike Huckman has been reporting from Gaithersburg, Md--where the U.S. Food and Drug Administration has convened a panel to decide the fate of drug-coated stents. Johnson & Johnson and Boston Scientific – the two major producers of stents – have been eagerly awaiting a decision.
-
Pfizer stock is down 13% so far today on news that development of its Lipitor successor – torceptrapib – has been halted. Analysts have downgraded the stock and cut price targets as a result. Barbara Ryan – managing director and senior analyst at Deutsche Bank – disagrees though. She appeared on “Morning Call” to say that the dip in price today is a buy-in opportunity.